Jazz Pharmaceuticals (NASDAQ:JAZZ) Trading Down 6.2% - Should You Sell?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report)'s share price fell 6.2% during mid-day trading on Wednesday . The stock traded as low as $98.25 and last traded at $96.40. 220,162 shares were traded during mid-day trading, a decline of 71% from the average session volume of 760,615 shares. The stock had previously closed at $102.82.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JAZZ shares. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Royal Bank of Canada dropped their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. HC Wainwright increased their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Finally, Barclays reissued an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $187.71.

Remove Ads

Jazz Pharmaceuticals Price Performance

The company has a fifty day moving average price of $129.67 and a two-hundred day moving average price of $122.77. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market cap of $6.18 billion, a P/E ratio of 14.33, a PEG ratio of 1.04 and a beta of 0.42.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock worth $4,023,305 in the last 90 days. Corporate insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. HighTower Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 37.2% during the third quarter. HighTower Advisors LLC now owns 7,594 shares of the specialty pharmaceutical company's stock worth $851,000 after purchasing an additional 2,060 shares during the period. Public Employees Retirement System of Ohio bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth $2,491,000. Barclays PLC lifted its holdings in shares of Jazz Pharmaceuticals by 19.1% during the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after buying an additional 6,289 shares in the last quarter. Coldstream Capital Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 7.7% during the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company's stock worth $259,000 after buying an additional 165 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 502.8% in the third quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company's stock valued at $1,310,000 after acquiring an additional 9,804 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.